Pharnext S.A.

  • WKN: A2AM02
  • ISIN: FR0011191287
  • Land: Frankreich

Nachricht vom 13.09.2017 | 17:47

Pharnext to Present at 7th Annual CEC Capital Summit

DGAP-News: Pharnext S.A. / Key word(s): Conference

13.09.2017 / 17:47
The issuer is solely responsible for the content of this announcement.


Pharnext to Present at 7th Annual CEC Capital Summit

Paris, France, 5:45pm, September 13, 2017 (CEST) - Pharnext SA (FR00111911287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that company management will present a corporate overview at the 7th Annual CEC Capital Summit.

The presentation will take place as follows:

  • Date: Wednesday, September 20th, 2017
  • Time: 2:50 pm PDT (11:50 pm CEST)
  • Venue: Montage Beverly Hills in Beverly Hills, California

If you are interested in meeting the Pharnext management team during this event, please send an email to Matthew Shinseki at matthew@sternir.com.

About Pharnext
Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer's disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY(TM). The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG(TM) offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.


The company Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR00111911287).

For more information, visit www.pharnext.com

CONTACTS:

Pharnext
Xavier Paoli
Chief Commercial Officer
contact@pharnext.com
+33 (0)1 41 09 22 30
 
   
Investor Relations (Europe)
MC Services AG
Anne Hennecke
anne.hennecke@mc-services.eu
+49 211 529252 22
 
Investor Relations (U.S.)
Stern Investor Relations, Inc.
Matthew Shinseki
matthew@sternir.com
+1 212-362-1200
 
Financial Communication (France)
New CAP
Emmanuel Huynh
pharnext@newcap.eu
+33 (0)1 44 71 20 40
 
Media Relations (Europe)
ALIZE RP
Caroline Carmagnol
Margaux Pronost
pharnext@alizerp.com  
+33 (0)1 44 54 36 64
 
 
Media Relations (U.S.)
Russo Partners
Tony Russo
Scott Santiamo
tony.russo@russopartnersllc.com 
scott.santiamo@russopartnersllc.com 
+1 212-845-4251
+1 718-344-5843
 


13.09.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


show this

GBC im Fokus

Euromicron: Positiver Trend setzt sich fort

Die Euromicron AG ist ein Technologieunternehmen, das auf die Digitalisierung von Infrastrukturen und die Vernetzung von IT-Strukturen spezialisiert ist. Euromicron ist gut in das GJ 2017 gestartet und konnte Umsatz und Ergebnis deutlich verbessern. Die vom Management jüngst umgesetzte Strategie, den Konzern auf wachstumsträchtige Geschäftsfelder wie „IoT“ (Internet of Things) oder „Digitalisierung“ auszurichten, trägt immer mehr Früchte. Aufgrund der zunehmenden Erschließung von „IoT“-Märkten und dem noch vorhandenen Synergie-Potenzial, gehen wir davon aus, dass dieser positive Trend umsatz- und ergebnisseitig fortgesetzt wird. Vor diesem Hintergrund vergeben wir das Rating KAUFEN und das Kursziel von 10,50 €.

News im Fokus

E.ON SE: E.ON in fortgeschrittenen Gesprächen hinsichtlich einer Vereinbarung, nach der die verbleibende Beteiligung an Uniper im Rahmen eines öffentlichen Übernahmeangebots von Fortum Anfang 2018 angedient werden könnte

20. September 2017, 12:03

Aktuelle Research-Studie

MOLOGEN AG

Original-Research: Mologen AG (von First Berlin Equity Research GmbH): BUY

22. September 2017